The British drugmaker’s remaining 4.2% stake in its consumer health arm Haleon also boosted its bottom line, following its spin off in July 2022
by OverviewFX | May 1, 2024 | Stocks
The British drugmaker’s remaining 4.2% stake in its consumer health arm Haleon also boosted its bottom line, following its spin off in July 2022